Mutual Advisors LLC Has $1.24 Million Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Mutual Advisors LLC cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,300 shares of the financial services provider’s stock after selling 300 shares during the period. Mutual Advisors LLC’s holdings in iShares Biotechnology ETF were worth $1,236,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter valued at about $29,000. Highline Wealth Partners LLC bought a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth approximately $36,000. Modus Advisors LLC acquired a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at $41,000. Finally, Voisard Asset Management Group Inc. bought a new position in iShares Biotechnology ETF in the 3rd quarter valued at about $59,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB opened at $137.30 on Friday. The stock has a 50 day simple moving average of $136.04 and a 200 day simple moving average of $141.80. iShares Biotechnology ETF has a 1-year low of $123.60 and a 1-year high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were given a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.